LON:AVCTAvacta Group Share Price, Forecast & News

GBX 164.50

+14.50 (+9.67 %)

(As of 06/5/2020 04:54 AM ET)

Add

Compare

Today's Range

146

Now: GBX 164.50▼

168

50-Day Range

MA: GBX 123.60▼

202

52-Week Range

12.62

Now: GBX 164.50▼

215.36

Volume1.94 million shs

Average Volume19,964 shs

Market Capitalization£343.47 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. It operates through two segments, Life Sciences and Animal Health. The company's custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development. In addition, it provides tools and contract services to assist the diagnosis of conditions in animals to enable treatment for veterinarians. The company has a collaboration, licensing, and option agreement with Moderna Therapeutics; research collaboration with OncoSec Medical Incorporated for gene delivery of therapeutic Affimers; and a co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Avacta Group.

2.5 Community Rank

Outperform Votes
Avacta Group has received 210 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Avacta Group has received 205 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Avacta Group has received 50.60% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Avacta Group and other stocks. Vote “Outperform” if you believe AVCT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVCT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Avacta Group does not currently pay a dividend.
Dividend Growth
Avacta Group does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avacta Group insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Avacta Group are expected to grow in the coming year, from GBX (11.05) to GBX 0 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Avacta Group is -18.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avacta Group is -18.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Avacta Group has a P/B Ratio of 7.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.63 out of 5 stars

Industry, Sector and Symbol

Stock Exchange LON

Industry Medical Devices

Sub-IndustryN/A

SectorMedical

Current SymbolLON:AVCT

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.avacta.com

Phone+44-1904-217070

Debt

Debt-to-Equity RatioN/A

Current Ratio6.92

Quick Ratio6.84

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales£3.89 million

Price / Sales88.29

Cash FlowGBX 5.68 per share

Price / Cash Flow28.98

Book ValueGBX 21.40 per share

Price / Book7.69

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees114

Outstanding Shares208,798,000

Market Cap£343.47 million

Next Earnings DateN/A

OptionableNot Optionable

Receive AVCT News and Ratings via Email

Sign-up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter.

Avacta Group (LON:AVCT) Frequently Asked Questions

How has Avacta Group's stock been impacted by COVID-19 (Coronavirus)?

Avacta Group's stock was trading at GBX 22.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AVCT stock has increased by 623.1% and is now trading at GBX 164.50. View which stocks have been most impacted by Coronavirus.

How were Avacta Group's earnings last quarter?

Avacta Group Plc (LON:AVCT) announced its quarterly earnings data on Tuesday, April, 9th. The biotechnology company reported ($4.80) earnings per share (EPS) for the quarter. View Avacta Group's earnings history.

Has Avacta Group been receiving favorable news coverage?

Headlines about AVCT stock have been trending negative on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avacta Group earned a media sentiment score of -2.7 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutAvacta Group.

Who are some of Avacta Group's key competitors?

Some companies that are related to Avacta Group include Avita Medical (AVH), Stratec (SBS), Zynex (ZYXI), Draegerwerk AG & Co KGaA (DRW3), Creo Medical Group (CREO), Hamilton Thorne (HTL), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), Medica Group (MGP), Electromed (ELMD), Electromed (ELMD), Cyclopharm (CYC), Patient Home Monitoring (PTQ), Advanced Oncotherapy (AVO), Somnomed (SOM) and Resonance Health (RHT). View all competitors.

What other stocks do shareholders of Avacta Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avacta Group investors own include Legal & General Group (LGEN), Skinbiotherapeutics (SBTX), Augean (AUG), Bunzl (BNZL), 7Digital Group (7DIG), Conviviality (CVR), ReNeuron Group (RENE), Bahamas Petroleum (BPC), Best of the Best (BOTB) and Blur Group (BLUR).

Who are Avacta Group's key executives?

Avacta Group's management team includes the following people:

Prof. Alastair Smith, CEO & Exec. Director
Mr. Tony Gardiner, CFO, Company Sec. & Exec. Director (Age 48)
Dr. Michael Albin, Adviser
Dr. Matt Johnson, Chief Technology Officer
Dr. Amrik Basran Ph.D., Chief Scientific Officer

What is Avacta Group's stock symbol?

Avacta Group trades on the London Stock Exchange (LON) under the ticker symbol "AVCT."

How do I buy shares of Avacta Group?

Shares of AVCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Avacta Group's stock price today?

One share of AVCT stock can currently be purchased for approximately GBX 164.50.

How big of a company is Avacta Group?

Avacta Group has a market capitalization of £343.47 million and generates £3.89 million in revenue each year. Avacta Group employs 114 workers across the globe.

What is Avacta Group's official website?

The official website for Avacta Group is www.avacta.com.

How can I contact Avacta Group?

Avacta Group's mailing address is Unit 20, Ash Way, WETHERBY, LS23 7FA, United Kingdom. The biotechnology company can be reached via phone at +44-1904-217070.

This page was last updated on 6/5/2020 by MarketBeat.com Staff